New prospects for drug discovery from structural studies of rhodopsin

Current Pharmaceutical Design

Volumn 11, Issue 17, 2005, Pages 2243-2256

  Bosch, L ^a   Iarriccio, L ^a   Garriga, Pere ^a  

^a UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

Author keywords

Drug design; G protein coupled receptors; Ligand binding domain; Molecular modeling; Rhodopsin structure; Site directed mutagenesis

Indexed keywords

ANTIPARKINSON AGENT; BACTERIAL PROTEIN; BACTERIORHODOPSIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; MU OPIATE RECEPTOR AGONIST; MUSCARINIC M1 RECEPTOR ANTAGONIST; NEW DRUG; RECEPTOR BLOCKING AGENT; RHODOPSIN; SENSORY RHODOPSIN; SEROTONIN 1 RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR;

CRYSTAL STRUCTURE; DIMERIZATION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; HUMAN; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THEORETICAL STUDY;

DRUG DESIGN; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, G-PROTEIN-COUPLED; RHODOPSIN; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 21044450541     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054367436     Document Type: Review

References (145)

1. Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999; 18: 1723-9.
2. Wess J. G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 1997; 11: 346-54.
3. Lomize AL, Pogozheva ID, Mosberg HI. Structural organization of G-protein-coupled receptors. J Comput Aided Mol Des 1999; 13:325-53.
4. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001; 22: 368-76.
5. Ji TH, Grossmann M, Ji I. G protein-coupled receptors. I. Diversity of receptor- ligand interactions. J Biol Chem 1998; 273: 17299-302.
6. Bockaert J, Claeysen S, Becamel C, Pinloche S, Dumuis A. G protein-coupled receptors: dominant players in cell-cell communication. Int Rev Cytol 2002; 212: 63-132.
7. Rohrer DK, Kobilka BK. G protein-coupled receptors: functional and mechanistic insights through altered gene expression. Physiol Rev 1998; 78: 35-52.
8. Druey KM. Regulators of G protein signalling: potential targets for treatment of allergic inflammatory diseases such as asthma. Expert Opin Ther Targets 2003; 7: 475-84.
9. Zhong H, Neubig RR. Regulator of G protein signaling proteins: novel multifunctional drug targets. J Pharmacol Exp Ther 2001; 297: 837-45.
10. Behan DP, Chalmers DT. The use of constitutively active receptors for drug discovery at the G protein-coupled receptor gene pool. Curr Opin Drug Discov Devel 2001; 4: 548-60.
11. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 2002; 3: 928-44.
12. Drews J. Drug discovery: A historical Prespective. Science 2000; 287: 1960-4.
13. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002; 7: 235-46.
14. Fung BK-K, Stryer L. Photolyzed rhodopsin catalyzes the exchange of GTP for bound GDP in retinal. Proc Natl Acad Sci USA 1980; 77: 2500-4.
15. Kuhn H, Bennett N, Michel-Villaz M, Chabre M. Interactions between photoexcited rhodopsin and GTP-binding protein: kinetic and stoichiometric analyses from light-scattering changes. Proc Natl Acad Sci USA 1981; 78: 6873-7.
16. Garriga P, Manyosa J. The eye photoreceptor protein rhodopsin. Structural implications for retinal disease. FEBS Lett 2002; 528: 17-22.
17. Rattner A, Sun H, Nathans J. Molecular genetics of human retinal disease. Annu Rev Genet 1999; 33: 89-131.
18. Dryja TP, Li T. Molecular genetics of retinitis pigmentosa. Hum Mol Genet 1995; 4: 1739-43.
19. Jacobson SG, Kemp CM, Sung CH, Nathans J. Retinal function and rhodopsin levels in autosomal dominant retinitis pigmentosa with rhodopsin mutations. Am J Ophthalmol 1991; 112: 256-71.
20. Themmen AP, Verhoef-Post M. LH receptor defects. Semin Reprod Med 2002; 20:199-204.
21. Strosberg AD. Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol 1997; 37:421-50.
22. Beukers MW, Kristiansen I, Ijzerman AP, Edvardsen I. TinyGRAP database: a bioinformatic tool to mine G-protein-coupled receptor mutant data. Trends Pharmacol Sci 1999; 20: 475-7.
23. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289:739-45.
24. Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001; 40: 7761-72.
25. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystal lography. Proc Natl Acad Sci USA 2002; 99: 5982-87.
26. Röper D, Jacoby E, Krüger P, Engels M, Grötzinger J, Wollmer A, et al. Modeling of G-protein coupled receptors with bacteriorhodopsin as a template. A novel approach based on interaction energy differences. J Recept Res 1994; 14: 167-86.
27. Luecke H, Schobert B, Richter HT, Cartailler JP, Lanyi JK. Structure of bacteriorhodopsin at 1.55 A resolution. J Mol Biol 1999; 291: 899-911.
28. Pebay-peyroula E, Rummel G, Rosenbusch JP, Landau EM. X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipid cubic phases. Science 1997; 277: 1676-81.
29. Luecke H, Richter HT, Lanyi JK. Proton transfer pathways in bacteriorhodopsin at 2.3 Å resolution. Science 1998; 280: 1934-7.
30. Takeda K, Sato H, Hino T, Kono M, Fukuda K, Sakurai I, et al. A novel Three-dimensional crystal of bacteriorhodopsin obtained by successive fusion of the vesicular assemblies. J Mol Biol 1998; 283: 463-74.
31. Baldwin JM. The probable arrengement of the helices in G protein-coupled receptors. EMBO J 1993: 12: 1693-703.
32. Stenkamp RE, Filipek S, Driessen CA, Teller DC, Palczewski K. Crystal structure of rhodopsin: a template for cone visual pigments and other G protein-coupled receptors Biochim Biophys Acta 2002; 1565: 168-82.
33. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptorsL: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 2001; 60: 1-19.
34. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000; 21: 90-113.
35. Attwood TK. A compendium of specific motifs for diagnosing GPCR subtypes. Trends Pharmacol. Sci. 2001; 22: 162-5.
36. O'Brien PJ, Zatz M. Acylation of bovine rhodopsin by [3H]palmitic acid. J Biol Chem 1984; 259: 5054-7.
37. Sadee W, Hoeg E, Lucas J, Wang D. Genetic variations in human G Protein- coupled receptor: implications for drug therapy. AAPS PharmSci 2001; 3: E22.
38. Johnson JA, Lima JJ. Drug receptor/effector polymorphisins and pharmacogenetics: current status and challenges. Pharmacogenetics 2003; 13: 525-34.
39. Oliveira L, Paiva ACM, Vriend G. A common motif in G-protein-coupled seven transmembrane helix receptors. J Comput Aided Mol Des 1993; 7: 649-58.
40. Ballesteros JA, Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-funtion relations in G-protein coupled receptors. Methods Neurosci 1995; 25: 366-428.
41. Hargrave PA. Rhodopsin structure, function, and topography. The Friedenwald Lecture. Invest Ophthalmol Vis Sci 2001; 42: 3-9.
42. Sakmar TP, Menon ST, Marin EP, Awad ES. Rhodopsin: insights from recent structural studies. Annu Rev Biophys Biomol Struct 2002; 31: 443-84.
43. Arshavsky VY, Lamb TD, Pugh EN Jr. G proteins and phototransduction. Annu Rev Physiol 2002; 64: 153-87.
44. Fukuda MN, Papermaster DS, Hargrave PA. Structural analysis of carbohydrate moiety of bovine rhodopsin. Methods Fnzymol 1982; 81: 214-23.
45. Karnik SS, Sakmar TP, Chen HB, Khorana HG. Cysteine residues 110 and 187 are essential for the formation of correct structure in bovine rhodopsin. Proc Natl Acad Sci USA 1988; 85: 8459-63.
46. Ridge KD, Lu Z, Liu X, Khorana HG. Structure and function in rhodopsin. Separation and characterization of the correctly folded and misfolded opsins produced on expression of an opsin mutant gene containing only the native intradiscal cysteine codons. Biochemistry 1995; 34: 3261-7.
47. Davidson FF, Loewen PC, Khorana HG. Structure and function in rhodopsin: replacement by alanine of cysteine residues 110 and 187, components of a conserved disulfide bond in rhodopsin. affects the light-activated metarhodopsin II state. Proc Natl Acad Sci USA 1994; 91: 4029-33.
48. Okada T., Fujiyoshi Y, Silow M. Navarro J. Landau EM, Shichida Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci USA 2002; 99: 5982-7
49. Bownds D. Site of attachment of retinal in rhodopsin. Nature 1967: 216: 1178-81.
50. Pepe IM. Recent advances in our understanding of rhodopsin and phototransduction. Prog Retin Eye Res 2001; 20: 733-59.
51. Menon ST, Han M, Sakmar TP. Rhodopsin: structural basis of molecular physiology. Physiol Rev 2001; 81: 1659-88.
52. Wald G. Carotenoids and the visual cycle. J Gen Physiol 1935; 19: 351-71.
53. Okada T, Ernst OP, Palczewski K, Hofmann KP. Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem Sci 2001; 26: 318-24.
54. Lu ZL, Saldanha JW, Hulme EC. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol Sci 2002; 23: 140-6.
55. Meng EC, Bourne HR. Receptor activation: what does the rhodopsin structure tell us?. Trends Pharmacol Sci 2001; 22: 587-93.
56. burns ME, Baylor DA. Activation, deactivation, and adaptation in vertebrate photoreceptor cells. Annu Rev Neurosci 2001; 24: 779-805.
57. Ridge KD, Abdulaev NG, Sousa M, Palczewski K. Phototransduction: crystal clear. Trends Biochem Sci 2003; 28: 479-87.
58. Schertler GF, Villa C, Henderson R. Projection structure of rhodopsin. Nature 1993; 362: 770-2.
59. Unger VM, Hargrave PA, Baldwin JM, Schertler GFX. Arrangement of rhodopsin transmembrane alpha-helices. Nature 1997; 389: 203-6.
60. Filipek S, Teller DC, Palczewski K, Stenkamp R. The cristallographic model or rhodopsin and its use in studies of other G Protein-Coupled Receptors. Annu Rev Biophys Biomol Struct 2003; 32: 375-97.
61. Riek RP, Rigoutsos I, Novotny J, Graham RM. Non-alpha-helical elements modulate polytopic membrane protein architecture. J Mol Biol 2001; 306: 349-62.
62. Visiers I, Ballesteros JA, Weinstein H. Prokink: a protocol for numerical evaluation of helix distortions by proline. Protein Eng 2000; 13: 603-6.
63. Filipek S, Stenkamp RE, Teller DC, Palczewski K. G protein-coupled receptor rhodopsin: a prospectus. Annu Rev Physiol 2003; 65: 851-79.
64. Mirzadegan T, Benko G, Filipek S, Palczewski K. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 2003; 42: 2759-67.
65. Ballesteros J, Kitanovic S, Guarnieri F, Davies P, Fromme BJ, Konvicka K, et al. Functional microdomains in G-protein-coupled receptors. The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor. J Biol Chem 1998; 273: 10445-53.
66. Fritze O, Filipek S, Kuksa V, Palczewski K, Hoffmann KP, Ernst OP. Role of the conserved NpxxY(x)5, 6F motif in the rhodopsin ground state and during activation. Proc Natl Acad Sci USA 2003; 100: 2290-5.
67. Sakmar TP, Franke RR, Khorana HG. Giutamic acid-113 serves as the retinylidene Schiff base counterion in bovine rhodopsin. Proc Natl Acad Sci USA 1989; 86: 8309-13.
68. Jager F, Fahmy K, Sakmar TP, Siebert F. Identification of glutamic acid 113 as the Schiff base proton acceptor in the metarhodopsin II photointermediate of rhodopsin. Biochemistry 1994; 33: 10878-82.
69. del Valle LJ, Ramon E, Canavate X, Dias P, Garriga P. Zinc-induced decrease of the thermal stability and regeneration of rhodopsin. J Biol Chem 2003; 278: 4719-24.
70. Stojanovic A, Stitham J, Hwa J. Critical role of transmembrane segment zinc binding in the structure and function of rhodopsin. J Biol Chem 2004. In press.
71. Becker OM, Shacham S, Marantz Y, Noiman S. Modeling the 3D structure of GPCRs: Advances and application to drug discovery. Curr Opin Drug Discovery 2003; 6: 353-61.
72. Tota MR, Candelore MR, Dixon RA, Strader CD. Biophysical and genetic analysis of the ligand-binding site of the β-adrenoceptor. Trends Pharmacol Sci 1991; 12: 4-6.
73. Savarese TM, Fraser CM. In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors. Biochem J 1992; 283: 1-19.
74. 1A -adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry 1996; 35: 14312-7.
75. 1AAdrenergic receptor subtype determinants for 4-piperidyl oxazole antagonists. Biochemistry 1998; 37: 5730-7.
76. Jacoby E, Fauchere JL, Raimbaud E, Ollivier S, Michel A, Spedding M. A three binding site hypothesis for the interaction of ligands with monoamine G protein-coupled receptors: Implications for combinatorial ligand design. Quant Struct Act Relatsh 1999; 18: 561-72.
77. Ji H, Zheng W, Zhang Y, Catt KJ, Sandberg K. Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor. Proc Natl Acad Sci USA 1995; 92: 9240-4.
78. Fong TM, Huang RR, Yu H, Strader CD. Mapping the ligand binding site of the NK1 receptor. Regul Pept 1993; 46: 43-8.
79. Cascieri MA, Shiao LL, Mills SG, MacCoss M, Swain CJ, Yu H, et al. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: Identification of a common binding site for structurally dissimilar antagonists. Mol Pharmacol 1995; 47: 660-5.
80. Alla SA, Quitterer U, Grigoriev S, Maidhof A, Haasemann M, Jamagin K, et al. Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies. J Biol Chem 1996; 271: 1748-55.
81. Soudijn W, Van Wijngaarden I, Ijzerman AP. Allosteric modulation of G protein-coupled receptors. Expert Opin Ther Pat 2001; 11: 1889-904.
82. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 2002; 1: 198-210.
83. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptors oligomerization and its potencial for drug discovery. Nat Rev Drug Discov 2002; 1: 808-20.
84. Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, Palczewski K. Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature 2003; 421: 127-8.
85. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K. Engel A. Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J Biol Chem 2003; 278: 21655-62.
86. Chabre M, Cone R, Saibil H. Is rhodopsin dimeric in native retinal rods? Nature 2003; 426: 30-31.
87. Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, Palczewski K. Is rhodopsin dimeric in native retinal rods? Nature 2003; 426: 31.
88. Cone PA. Rotational diffusion of rhodopsin in the visual receptor membrane. Nature New Biol 1972; 236: 39-43.
89. Roof DJ, Heuser JE. Surfaces of rod photoreceptor disk membranes: integral membrane components. J Cell Biol 1982; 95: 487-500.
90. Halazy S, Perez M, Fourrier C, Pallard I, Pauwels PJ, Palmier C, et al. Serotonin dimers: application of the bivalent ligand approach to the design of a new potent and selective 5-HT(1B/1D) agonists. J Med Chem 1996; 39: 4920-7.
91. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002; 277: 18091-7.
92. Milligan G. G protein-coupled receptor dimerization: Function and ligand pharmacology. Mol Pharmacol 2004; 66: 1-7.
93. Maggio R, Scarselli M, Novi F, Milian MJ, Corsini GU. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 2003; 87: 631-41.
94. Wang Q, Schoenlein RW, Peteanu LA, Mathies RA, Shank CV. Vibrationally coherent photochemistry in the femtosecond primary event of vision. Science 1994; 266: 422-24.
95. Matthews RG, Hubbard R, Brown PK, Wald G. Tautomeric forms of metarhodopsin. J Gen Physiol 1963; 47: 215-40.
96. Choi G, Landin J, Galan JF, Birge RR, Albert AD, Yeagle PL. Structural studies of metarhodopsin II, the activated form of the G-protein coupled receptor, rhodopsin. Biochemistry 2002; 41: 7318-24.
97. Bissantz C. Conformational changes of G protein-coupled receptors during their activation by agonist binding. J Recept Signal Transduct Res 2003; 23: 123-53.
98. Gether U, Asmar F, Meinild AK, Rasmussen SG. Structural basis for activation of G-protein-coupled receptors. Pharmacol Toxicol 2002; 91: 304-12.
99. Stryer L. Cyclic GMP cascade of vision. Annu Rev Neurosci 1986; 9: 87-119.
100. Heck M, Schadel SA, Maretzki D, Bard FJ, Ritter E, Palczewski K, et al. Signaling states of rhodopsin. Formation of the storage form, metarhodopsin III, from active metarhodopsin II. J Biol Chem 2003; 278: 3162-9.
101. Vogel R, Siebert F, Zhang XY, Fan G, Sheves M. Formation of Meta III during the decay of activated rhodopsin proceeds via Meta I and not via Meta II. Biochemistry 2004; 43: 9457-66.
102. Samama P, Cotecchia S, Costa T, Kefkowitz RJ. A mutation-induced activated state of the β2-adrenergic receptor: extending the TCM. J Biol Chem 1993; 268: 4625-36.
103. Weiss J, Morgan P, Lutz M, Kenakin T. The cubic ternary complex receptor occupancy model. I. Model description. J Theor Biol 1996; 178: 151-67.
104. Weiss J, Morgan, P, Lutz M, Kenakin T. The cubic ternary complex receptor occupancy model. II. Understanding apparent affinity. J Theor Biol 1996; 178: 169-82.
105. Kenakin T. Ligand-selective receptors conformations revisited: the promise and the problem. Tips 2003; 24: 346-54.
106. Chen CY, Cordeaux Y, Hill SJ, King JR. Modelling of signalling via G-protein coupled receptors: pathway-dependent agonist potency and efficacy. Bulletin of Mathematical Biology 2003; 65: 933-58.
107. Brink CB, Harvey BH, Bodenstein J, Venter DP, Oliver DW. Recent advances in drug action and therapeutics: Relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology. Br J Clin Pharmacol 2004; 57: 373-87.
108. Brink CB. Protean behavior by agonists: agonist-directed trafficking of receptor signaling. Tips 2002; 23: 454-5.
109. Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, Graham RM. Constitutive activation of a single effector pathway: evidence of multiple activation states of a G protein-coupled receptor. Mol Pharmacol 1996; 49:112-22.
110. Farrar GJ, Kenna PF, Humphries P. On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J 2002; 21: 857-64.
111. van Soest S, Westerveld A, de Jong PT, Bleeker-Wagemakers EM, Bergen AA. Retinitis pigmentosa: defined from a molecular point of view. Surv Ophthalmol 1999; 43: 321-34.
112. Ramon E, del Valle LJ, Garriga P. Unusual thermal and conformational properties of the rhodopsin congenital night blindness mutant Thr-94-Ile. J Biol Chem 2003; 278: 6427-32.
113. Hubbell WL, Altenbach C, Khorana HG. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv Protein Chem 2003; 63: 243-90.
114. Nikiforovich GV, Marshall GR. Three-dimensional model for meta-II rhodopsin, an activated G-protein-coupled receptor. Biochemistry 2003; 42: 9110-20.
115. Acharya S, Saad Y, Karnik SS. Transducin-α C-terminal peptide binding site consists of C-D and E-F loops of rhodopsin. J Biol Chem 1997; 272: 6519-24.
116. Arimoto R, Kisselev OG, Makara GM, Marshall GR. Rhodopsin-transducin interface: studies with conformationally constrained peptides. Biophys J 2001; 81: 3285-93.
117. Fahmy K, Sakmar TP, Siebert F. Transducin-depend protonation of glutamic acid 134 in rhodopsin. Biochemistry 2000; 39: 10607-12.
118. Arnis S, Hofmann KP. Two different forms of metarhodopsin II: Schiff base deprotonation precedes proton uptake and signaling state. Proc Natl Acad Sci USA 1993; 90: 7849-53.
119. Scheer A, Fanelli F, Costa T, De Benedetti PG, Cotecchia S. The activation process of the 1-β-adrenergic receptor: potential role of protonation and hydrophobicity of a highly conserved aspartate. Proc Natl Acad Sci USA 1997; 94: 808-13.
120. Seibert C, Harteneck C, Ernst OP, Schultz G, Hofmann KP. Activation of the rod G-protein Gt by the thrombin receptor (PAR1) expressed in Sf9 cells. Eur J Biochem 1999; 266: 911-16.
121. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
122. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
123. Cacace A, Banks M, Spicer T, Civoli F, Watson J. An ultra-HTS process for the identification of small molecules modulators of orphan G-protein-coupled receptors. Drug Discov Today 2003; 17: 785-92.
124. Bissantz C, Bernard P, Hibert M, Rognan D. Protein-Based Virtual Screening of Chemical Databases-II. Are Homology Models of G-Protein Coupled Receptors Suitable Targets? Proteins: Structure, Function, and Genetics 2003; 50: 5-25.
125. Mason JS, Morize I, Menard PR, Cheney DL, Hulme C, Labaudiniere RF. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J Med Chem 1999; 42: 3251-64.
126. Waszkowycz B, Perkins TDJ, Sykes RA, Li J. Large-scale virtual screening for discovery leads in the postgenomics era. IBM Syst J 2001; 40: 360-76.
127. Ballesteros J, Palczewski K. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr Opin Drug Discov Devel 2001; 4: 561-74.
128. Dixon JS. Evaluation of the CASP2 docking section. Proteins 1997; (Suppl 1): 198-204.
129. Tame JRH. Scoring functions: a view firom the bench. J Comput Aided Mol Des 1999; 13: 99-108.
130. Bohacek R, McMartin C. Modern computational chemistry and drug discovery: structure generating programs. Curr Opin Chem Biol 1997; 1: 157-61.
131. Shoichet B, McGovern S, Wei B, Irwin J. Lead discovery using molecular docking. Curr Opin Chem Biol 2002; 6: 439-46.
132. Fiser A, Sanchez R, Melo F, Sali A. Comparative protein structure modeling. In: Becker OM, MacKerell AD Jr, Roux B, Watanabe M (Eds), Computational Biochemistry and Biophysics. Marcel Dekker, New York, NY, USA 2001; 275-312.
133. 2B receptors. Molecular modeling and site-directed mutagenesis. J Biol Chem 2002; 277: 17170-78.
134. Underwood DJ, Strader CD, Rivero R, Patchett AA, Greenlee W, Prendergast K. Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Chem Biol 1994; 1: 211-221.
135. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: Binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 2000; 275: 25562-71.
136. Marvin C, Gershengorn, Osman R. Insights into G protein-coupled receptor function using molecular models. Endocrinology 2001; 142: 2-10.
137. Osman R, Colson A-O, Perlman JH, Laakkonen LJ, Gershengorn MC. Mapping binding sites for peptide G protein-coupled receptors: The receptor for thyrotropin-releasing hormone. In: Wess J (ed) Structure/Function of G-Protein Coupled Receptors. John Wiley & Sons, New York 1999; 59-84.
138. Ter Laak AM, Timmerman H, Leurs R, Nederkoorn PH, Smit MJ, Donne-Op den Kelder GM. Modelling and mutation studies on the histamine H1-receptor agonist binding site reveal different binding modes for H1-agonists: Asp116 (TM3) has a constitutive role in receptor stimulation. J Comput Aided Mol Des 1995; 9: 319-30.
139. Green SA, Spasoff AP, Coleman R-A, Johnson M, Liggett SB. Sustained activation of a G protein-coupled receptor via 'anchored' gonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 1996; 271: 24029-35.
140. Gutiérrez-de-Terán H, Centeno NB, Pastor M, Sanz F. Novel approaches for modeling of tile A1 adenosine receptor and its agonist binding sites. Proteins 2004; 54: 705-15.
141. Archer E, Maigret B, Escrieut C, Pradyrol L, Fourmy D. Rhodopsin crystal: new template yielding realistic models og G-protein-coupled receptors? Trends Pharmacol Sci 2003; 24: 36-40.
142. Sakmar TP. Structure of rhodopsin and the superfamily of sevenhelical receptors: the same or not the same. Curr Opin Cell Biol 2002; 14: 189-95.
143. 2A receptor derived from an in silico activated G-protein coupled receptor. J Comput Aided Mol Des 2002; 16: 511-20.
144. Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, et al. Prediction of structure and function of G protein-coupled receptors. Proc Natl Acad Sci USA 2002; 99: 12622-27.
145. Shacham S, Topf M, Avisar N, Glaser F, Marantz Y, Bar-Haim S, et al. Modeling the 3D structure of GPCRs from sequence. Med Res Rev 2001; 21: 472-83.